West Valley Medical Center is proud to announce the use of a new technology for heart patients. The U.S. Food and Drug Administration (FDA) recently approved the drug-coated balloon (DCB), a groundbreaking therapy designed to treat coronary in-stent restenosis (ISR) in patients with coronary artery disease (CAD). The new technology marks a significant step forward in advancing patient care, as ISR is a challenging condition where a stented vessel becomes narrowed or blocked by plaque or scar tissue.
This particular technology, the DCB, has successfully treated more than 100,000 patients globally in both clinical and commercial settings.
“We are thrilled to introduce this proven and safe therapy to our patients,” said Dr. Lyndon Box, Interventional Cardiologist, West Valley Medical Group. “The DCB addresses a critical unmet need in coronary artery disease treatment by offering a dedicated solution for ISR.”
This therapy is an alternative to traditional therapies such as balloon angioplasty, additional layers of stenting, or radiation, providing a paclitaxel-coated balloon catheter that delivers a therapeutic dose of drug to the vessel wall, preventing the reoccurrence of ISR.